Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CORT | CLUSTER | neutral | 3/10 | Corcept Therapeutics insiders Sean Maduck and Joseph Lyon sold shares in open-market transactions totaling ~$141K on Oct | Oct 5, 2026 |
| ROIV | CLUSTER | bearish | 4/10 | Roivant Sciences insiders executed $7.93M in net selling, dominated by President & Immunovant CEO Eric Venker's open-mar | Oct 5, 2026 |
| MNPR | CLUSTER | bearish | 4/10 | Monopar Therapeutics insiders executed a cluster of non-cash derivative exercises and tax-withholding share surrenders o | Oct 5, 2026 |
| UTHR | CLUSTER | bearish | 5/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$818K in open-market sales on October 1-2, 2026. The CEO's sal | Oct 5, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Two C-suite insiders at Castle Biosciences sold a total of ~$136K in open-market sales over a 3-day period. The Chief Co | Oct 5, 2026 |
| TWST | CLUSTER | bearish | 5/10 | Two insiders at Twist Bioscience sold a combined $2.08M in open-market sales on the same day, including the Chief Accoun | Oct 5, 2026 |
| SYRE | CLUSTER | bearish | 4/10 | Two top executives at Spyre Therapeutics (CEO and CFO) sold a combined $377K of stock on the same day (October 1, 2026) | Oct 2, 2026 |
| ORIC | CLUSTER | neutral | 3/10 | Two ORIC insiders, including the CFO, sold shares in a cluster totaling $223K in open-market sales. The CFO's sale was a | Oct 2, 2026 |
| ORMP | CLUSTER | neutral | 3/10 | Two C-suite insiders at Oramed Pharmaceuticals sold a combined $226K in open-market sales on the same day, with no indic | Oct 2, 2026 |
| VSTM | CLUSTER | bearish | 5/10 | CEO Dan Paterson and CFO Daniel Calkins sold a combined $373K in open-market sales on October 1, 2026, at $8.00/share. T | Oct 2, 2026 |
| LEEEF | CLUSTER | bullish | 4/10 | Three insiders at Leef Brands Inc., including the CEO and CFO, made open-market purchases totaling $137K at $0.25/share | Oct 2, 2026 |
| XERS | CLUSTER | neutral | 3/10 | Two Xeris Biopharma insiders sold a combined $407K in open-market transactions over a one-week window, with no insider b | Oct 2, 2026 |
| ONC | CLUSTER | bearish | 5/10 | Director Wang Xiaodong executed a large derivative exercise of 434,392 shares (31,028 at $36.9 + 403,364 at $0) and simu | Oct 2, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $559K in open-market shares over two days, following derivative | Oct 2, 2026 |
| MAZE | CLUSTER | bearish | 4/10 | Two Maze Therapeutics insiders, including CEO Jason Coloma, sold a total of $1.07M in open-market sales over a one-week | Oct 1, 2026 |
| RVMD | CLUSTER | neutral | 4/10 | Multiple RVMD insiders, including the Chief Development Officer and General Counsel, sold a combined $1.40M in open-mark | Oct 1, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$3.8M worth of UTHR shares on 2026-09-30 across 18 open-market trades, while EVP & General C | Oct 1, 2026 |
| RAPP | CLUSTER | neutral | 3/10 | Two insiders at Rapport Therapeutics sold a total of $270K in shares over a one-week window in late September 2026. The | Oct 1, 2026 |
| XENE | CLUSTER | bullish | 6/10 | Xenon Pharmaceuticals' CEO and CFO made open-market purchases totaling $1.68M on the same day, with the CEO alone buying | Oct 1, 2026 |
| ADRX | CLUSTER | bullish | 7/10 | Director and 10% owner George Simeon made two large open-market purchases totaling ~$17.1M at $17/share, while another 1 | Sep 30, 2026 |
| ANIX | CLUSTER | bullish | 5/10 | Four Anixa insiders, including the CEO, President/CFO, and two directors, made open-market purchases totaling $181K over | Sep 30, 2026 |
| ABEO | CLUSTER | bearish | 4/10 | Three senior insiders at Abeona Therapeutics (CFO, Chief Legal Officer, Chief Commercial Officer) sold a combined ~$107K | Sep 29, 2026 |
| ADRX | CLUSTER | bullish | 6/10 | Director and 10% owner George Simeon made two open-market purchases totaling ~$17.1M at $17/share, while 10% owner SR ON | Sep 29, 2026 |
| DFTX | CLUSTER | bearish | 5/10 | Two C-suite insiders at Definium Therapeutics (CFO and CLO) sold a combined $637K in open-market sales at $36.57 per sha | Sep 29, 2026 |
| RPRX | CLUSTER | bearish | 5/10 | Two Royalty Pharma executives sold a combined $5.86M in open-market sales over a one-week window. EVP & Chairman Hite Ch | Sep 29, 2026 |
| KURA | CLUSTER | bearish | 5/10 | Four Kura Oncology insiders, including the CSO, COO, CMO, and SVP of Finance, sold a total of ~$476K in open-market shar | Sep 29, 2026 |
| RVMD | CLUSTER | neutral | 3/10 | Three Revolution Medicines insiders sold a total of ~$804K in open-market sales over a 7-day window, with the largest sa | Sep 29, 2026 |
| RVMD | CLUSTER | neutral | 3/10 | Two insiders at Revolution Medicines sold a total of $645K in stock over a week. Director Elizabeth Anderson exercised a | Sep 28, 2026 |
| INBX | CLUSTER | bullish | 5/10 | Two INBX insiders — CEO Mark Lappe and Director Jon Faiz Kayyem — made open-market purchases totaling $829K over a week, | Sep 28, 2026 |
| ANIX | CLUSTER | bullish | 4/10 | Two Anixa insiders, including the CEO and a director, made open-market purchases totaling $151K in late September 2026. | Sep 28, 2026 |